Advertisement

Index by author

February 01, 1995; Volume 23,Issue 2

A

  1. Abadìa, A R

    1. Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;

  2. Andrews, P A

    1. Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).
      M Jennerwein and P A Andrews
      Drug Metabolism and Disposition February 1995, 23 (2) 178-184;

  3. Arison, B H

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

B

  1. Balani, S K

    1. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
    2. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  2. Benoit, E

    1. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

  3. Burka, L T

    1. Metabolism and elimination of oxazepam in F344 rats.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition February 1995, 23 (2) 232-239;

  4. Buronfosse, T

    1. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

C

  1. Chakravarty, P K

    1. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;

  2. Chen, I W

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  3. Chen, R

    1. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;

  4. Chenery, R J

    1. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;

  5. Cheraghali, A M

    1. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;

  6. Ching, M S

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

  7. Chiu, S H

    1. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;

  8. Cho, A K

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

  9. Chu, T Y

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

  10. Clarke, S E

    1. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;

D

  1. De Francesco, L

    1. Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;

  2. Delatour, P

    1. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

  3. Distefano, E W

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

  4. Divakaruni, P

    1. Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;

  5. Du Souich, P

    1. Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;

E

  1. el Mansouri, S

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

G

  1. Geerts, R J

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

  2. Ghabrial, H

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

  3. Griffin, R J

    1. Metabolism and elimination of oxazepam in F344 rats.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition February 1995, 23 (2) 232-239;

  4. Guaitani, A

    1. Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;

  5. Guengerich, F P

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

H

  1. Harrell, A W

    1. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;

  2. Héroux, L

    1. Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;

  3. Heykants, J J

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

  4. Hiratsuka, A

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

J

  1. Jamali, F

    1. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis.
      M Piquette-Miller and F Jamali
      Drug Metabolism and Disposition February 1995, 23 (2) 240-245;

  2. Jennerwein, M

    1. Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).
      M Jennerwein and P A Andrews
      Drug Metabolism and Disposition February 1995, 23 (2) 178-184;

  3. Jeong, H G

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

K

  1. Kauffman, L R

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  2. Knaus, E E

    1. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;

  3. Kumar, R

    1. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;

L

  1. Laurenzana, E M

    1. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;

  2. Leclerq, M

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

  3. Lee, H

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

  4. Lee, H S

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

  5. Lin, J H

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  6. Lin, L Y

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

  7. Liu, Z C

    1. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;

  8. Longin-Sauvageon, C

    1. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

M

  1. Mathai, L

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  2. Matsunaga, T

    1. Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;

  3. Maurice, H

    1. Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;

  4. McClelland, R A

    1. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;

  5. Meuldermans, W E

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

  6. Miller, R R

    1. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  7. Morgan, D J

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

  8. Moroni, P

    1. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

  9. Mugford, C A

    1. Contribution of oxidation and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidney from male and female Sprague-Dawley rats.
      C A Mugford and J B Tarloff
      Drug Metabolism and Disposition February 1995, 23 (2) 290-294;

O

  1. Owens, S M

    1. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;

P

  1. Pang, K S

    1. Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
      K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 166-177;
    2. Benzoic acid glycine conjugation in the isolated perfused rat kidney.
      K Poon and K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 255-260;

  2. Perret, G

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

  3. Petitjean, O

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

  4. Piquette-Miller, M

    1. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis.
      M Piquette-Miller and F Jamali
      Drug Metabolism and Disposition February 1995, 23 (2) 240-245;

  5. Pitzenberger, S M

    1. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;

  6. Poon, K

    1. Benzoic acid glycine conjugation in the isolated perfused rat kidney.
      K Poon and K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 255-260;

  7. Porthault, M

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

R

  1. Ramjit, H G

    1. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;

  2. Rho, J K

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

  3. Ring, J A

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

S

  1. Schmitz, D A

    1. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

  2. Schwartz, M S

    1. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;

  3. Shulkes, A

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

  4. Smallwood, R A

    1. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

  5. Sorrels, S L

    1. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;

  6. Stearns, R A

    1. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
    2. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

  7. Svensson, C K

    1. Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;

T

  1. Tarloff, J B

    1. Contribution of oxidation and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidney from male and female Sprague-Dawley rats.
      C A Mugford and J B Tarloff
      Drug Metabolism and Disposition February 1995, 23 (2) 290-294;

  2. Thompson, W J

    1. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;

  3. Tod, M

    1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

U

  1. Uetrecht, J P

    1. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;

V

  1. Van Beijsterveldt, L E

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

W

  1. Ware, J A

    1. Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;

  2. Watanabe, K

    1. Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;

  3. Wiebe, L I

    1. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;

  4. Woestenborghs, R J

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

  5. Wuyts, K

    1. Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

Y

  1. Yamamoto, I

    1. Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;

  2. Yashimura, H

    1. Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;

  3. Yeleswaram, K

    1. Relevance of tissue distribution studies.
      K Yeleswaram
      Drug Metabolism and Disposition February 1995, 23 (2) 159;

  4. Yun, C H

    1. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
Back to top

In this issue